Breaking News

Kincell Bio Completes $22M Investment Round 

NewSpring Capital and Kineticos Life Sciences led this investment round.

By: Rachel Klemovitch

Assistant Editor

Kincell Bio announced the completion of a $22 million round, led by a new investor, NewSpring Capital, through its healthcare strategy, NewSpring Healthcare. Existing investor Kineticos Life Sciences also led the round. Kincell Bio is a scientifically focused, cell therapy development and manufacturing company. This funding marks a significant milestone in Kincell Bio’s mission to transform the delivery of advanced cell therapies to patients worldwide.  This new investment will accele...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters